Pharmaceuticals in the Netherlands

Pharmaceuticals in the Netherlands


November 21, 2012
35 Pages - SKU: MTLN4921112
License type:
Online Download      US $350.00
Global Site License      US $875.00
Countries covered: Netherlands

Introduction

Pharmaceuticals in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market size (value 2007-11, and forecast to 2016). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Netherlands pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights
  • The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
  • The Dutch pharmaceuticals market had total revenues of $6.6 billion in 2011, representing a compound annual growth rate (CAGR) of 0.6% between 2007 and 2011.
  • The performance of the market is forecast to decelerate, with an anticipated CAGR of 0.1% for the five-year period 2011 - 2016, which is expected to drive the market to a value of $6.6 billion by the end of 2016.
Features

Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in the Netherlands

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in the Netherlands

Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Netherlands pharmaceuticals market with five year forecasts

Macroeconomic indicators provide insight into general trends within the Netherlands economy

Key Questions Answered

What was the size of the Netherlands pharmaceuticals market by value in 2011?

What will be the size of the Netherlands pharmaceuticals market in 2016?

What factors are affecting the strength of competition in the Netherlands pharmaceuticals market?

How has the market performed over the last five years?



More Country Overviews reports by MarketLine

Pharmaceuticals in Asia-Pacific by MarketLine
IntroductionPharmaceuticals in Asia-Pacific industry profile provides top-line qualitative and quantitative summary information including: market size (value 2007-11, and forecast to 2016). The profile also contains ...
Pharmaceuticals: Global Industry Guide by MarketLine
Pharmaceuticals: Global Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals: Global Industry Guide industry. It includes detailed data on ...
Pharmaceuticals: Global Industry Almanac by MarketLine
Pharmaceuticals: Global Industry Almanac is an essential resource for top-level data and analysis covering the Pharmaceuticals industry. It includes detailed data on market size and ...
Pharmaceuticals - North America (NAFTA) Industry Guide by MarketLine
Pharmaceuticals - North America (NAFTA) Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the North ...
See all reports like this >>

More Netherlands Country Overviews reports

Netherlands Pharmaceuticals and Healthcare Report Q2 2014 by Business Monitor International
Netherlands Pharmaceuticals and Healthcare Report Q2 2014BMI View: We anticipate further restrictions to medicine prices in 2014 under the Medicines Prices Act,which will subdue the ...
Netherlands Pharmaceuticals and Healthcare Report Q1 2013 by Business Monitor International
BMI View: While the Netherlands is a low-risk market from the point of view of multinationaldrugmakers, the country's modest per capita expenditure on pharmaceuticals relative ...
Netherlands Pharmaceuticals and Healthcare Report Q4 2012 by Business Monitor International
BMI View: The Netherlands remains ranked top in the 2012 version of the Euro Health Consumer Index, which is compiled by Swedish company Health Consumer ...
Netherlands Pharmaceuticals and Healthcare Report Q3 2012 by Business Monitor International
BMI View: While the Netherlands is a low risk market from the point of view of multinational drugmakers, the country’s modest per capita expenditure on ...
See all reports like this >>

More Netherlands reports

D&B Country RiskLine Report: The Netherlands by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: The Netherlands by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
See all reports like this >>